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Background
In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in 
combination with peginterferon–ribavirin, as compared with peginterferon–ribavirin 
alone, has shown improved efficacy, with potential for shortening the duration of treat-
ment in a majority of patients.
Methods
In this international, phase 3, randomized, double-blind, placebo-controlled trial, we 
assigned 1088 patients with HCV genotype 1 infection who had not received previous 
treatment for the infection to one of three groups: a group receiving telaprevir com-
bined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR group), fol-
lowed by peginterferon–ribavirin alone for 12 weeks if HCV RNA was undetectable 
at weeks 4 and 12 or for 36 weeks if HCV RNA was detectable at either time point; 
a group receiving telaprevir with peginterferon–ribavirin for 8 weeks and placebo 
with peginterferon–ribavirin for 4 weeks (T8PR group), followed by 12 or 36 weeks 
of peginterferon–ribavirin on the basis of the same HCV RNA criteria; or a group 
receiving placebo with peginterferon–ribavirin for 12 weeks, followed by 36 weeks 
of peginterferon–ribavirin (PR group). The primary end point was the proportion 
of patients who had undetectable plasma HCV RNA 24 weeks after the last planned 
dose of study treatment (sustained virologic response).
Results
Significantly more patients in the T12PR or T8PR group than in the PR group had a 
sustained virologic response (75% and 69%, respectively, vs. 44%; P<0.001 for the com-
parison of the T12PR or T8PR group with the PR group). A total of 58% of the patients 
treated with telaprevir were eligible to receive 24 weeks of total treatment. Anemia, 
gastrointestinal side effects, and skin rashes occurred at a higher incidence among 
patients receiving telaprevir than among those receiving peginterferon–ribavirin 
alone. The overall rate of discontinuation of the treatment regimen owing to adverse 
events was 10% in the T12PR and T8PR groups and 7% in the PR group.
Conclusions
Telaprevir with peginterferon–ribavirin, as compared with peginterferon–ribavirin 
alone, was associated with significantly improved rates of sustained virologic response 
in patients with HCV genotype 1 infection who had not received previous treatment, 
with only 24 weeks of therapy administered in the majority of patients. (Funded by Ver-
tex Pharmaceuticals and Tibotec; ADVANCE ClinicalTrials.gov number, NCT00627926.)
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Patients with chronic hepatitis C virus (HCV) infection are at risk for progressive he-patic fibrosis, cirrhosis, portal hypertension, 
hepatic failure, and hepatocellular carcinoma.1-4 
For the past decade, treatment with pegylated inter-
feron (peginterferon alfa) and ribavirin has been as-
sociated with rates of sustained virologic response 
of 40 to 50% among patients with HCV genotype 1 
who had received no previous treatment.5-7 At least 
48 weeks of treatment is required for most of these 
patients, and toxic effects may limit the extent of 
treatment in some patients.5-7
Telaprevir, a linear peptidomimetic HCV NS3/4A 
serine protease inhibitor, was associated with sub-
stantial improvements in response rates in phase 2 
studies when it was combined with peginterferon–
ribavirin.8-10 Moreover, high rates of early viral sup-
pression and low rates of relapse after cessation of 
telaprevir therapy suggested that therapy could po-
tentially be shortened to 24 weeks in patients who 
have a rapid virologic response — that is, patients 
in whom HCV RNA is undetectable at week 4 of 
treatment.8-10 A phase 3 study was conducted to 
evaluate the efficacy and safety of telaprevir-based 
therapy, administered in a regimen that was guided 
by the patient’s response, among patients who had 
received no previous treatment for HCV infection.
Me thods
Patients
We enrolled patients at 123 international sites. Eli-
gible patients were 18 to 70 years of age and had 
HCV genotype 1 infection with evidence of chron-
ic hepatitis, as confirmed by means of a liver biopsy 
within 1 year before screening for the study; pa-
tients with compensated liver cirrhosis were eli-
gible. Additional eligibility criteria included sero-
negativity for hepatitis B surface antigen, and the 
absence of antibodies against human immunode-
ficiency virus types 1 and 2, absolute neutrophil 
counts of 1500 or more per cubic millimeter, 
platelet counts of 90,000 or more per cubic milli-
meter, and hemoglobin levels of at least 12 g per 
deciliter in the case of women or 13 g per deciliter 
in the case of men. Patients were excluded if they 
had decompensated liver disease, liver disease 
from other causes, or hepatocellular carcinoma.
Study Design
This study was a phase 3, randomized, double-blind 
trial, placebo-controlled for telaprevir. Patients were 
stratified according to genotype 1 subtype (a, b, 
or unknown) and baseline viral load (HCV RNA 
<800,000 IU per milliliter or ≥800,000 IU per 
milliliter) and were randomly assigned to one of 
three treatment groups. The study was designed to 
evaluate two regimens of telaprevir (Vertex Phar-
maceuticals) of different durations, combined with 
peginterferon alfa-2a (Pegasys, Roche) and riba-
virin (Copegus, Roche), as compared with a regi-
men of peginterferon alfa-2a and ribavirin alone. 
The total duration of treatment was either 24 or 
48 weeks. During the first 12 weeks, patients as-
signed to one of the telaprevir groups received 
telaprevir and peginterferon–ribavirin either for 
the entire 12 weeks (T12PR group) or for 8 weeks 
followed by 4 weeks of placebo and peginterferon–
ribavirin (T8PR group). Patients in the T12PR and 
T8PR groups who met the criteria for an extended 
rapid virologic response (defined as undetectable 
HCV RNA at weeks 4 and 12) received 12 addi-
tional weeks of treatment with peginterferon–
ribavirin alone, for a total treatment period of 
24 weeks. Patients in the T12PR and T8PR groups 
who had detectable HCV RNA either at week 4 
or at week 12 received 36 additional weeks of 
treatment with peginterferon–ribavirin, for a to-
tal treatment period of 48 weeks. The group re-
ceiving peginterferon alfa-2a and ribavirin alone 
(PR group) received placebo plus peginterferon–
ribavirin for 12 weeks, followed by peginterferon–
ribavirin alone for 36 additional weeks. Telaprevir 
was administered orally at a dose of 750 mg every 
8 hours with food, peginterferon alfa-2a by subcu-
taneous injection at a dose of 180 μg per week, and 
ribavirin orally at a dose of 1000 mg per day (in 
patients who weighed less than 75 kg) or 1200 mg 
per day (in patients who weighed 75 kg or more).
Stopping rules were implemented to prevent the 
continuation of treatment in patients who did 
not have an adequate response. Patients receiv-
ing telaprevir who had HCV RNA levels greater 
than 1000 IU per milliliter at week 4 discontin-
ued telaprevir but continued peginterferon–riba-
virin. All patients with less than a 2 log10 de-
crease from baseline in HCV RNA levels at week 
12 discontinued treatment. Patients discontinued 
treatment if HCV RNA was confirmed to be de-
tectable at any time between weeks 24 and 40.
Study Oversight
The protocol was designed by Vertex Pharmaceu-
ticals and Tibotec in collaboration with one of the 
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academic authors. The protocol, which is available 
with the full text of this article at NEJM.org, was 
approved by an independent or institutional review 
board at each participating center, and all patients 
provided written informed consent before par-
ticipating in study-related activities. The corre-
sponding author prepared the first draft of the 
manuscript and made the decision to submit the 
manuscript for publication, and all the authors, to-
gether with an employee of the sponsor, assisted in 
the revision of subsequent drafts. All the authors 
reviewed and approved the final draft of the man-
uscript and assume responsibility for the accuracy 
and completeness of the data and data analyses and 
for the fidelity of the study to the trial protocol.
Efficacy Assessments
Plasma HCV RNA levels were measured with the 
use of the COBAS TaqMan HCV RNA assay, version 
2.0 (Roche), with a lower limit of quantification 
of 25 IU per milliliter and a lower limit of detection 
of 10 IU per milliliter. The lower limit of detec-
tion was used in the determination of extended 
rapid virologic response. HCV RNA levels were 
measured on day 1 and at weeks 1, 2, 3, 4, 6, 8, 
10, 12, 16, 20, 24, 28, 36, 40, and 48; at follow-up 
visits 4 weeks after the end of treatment; and at 
weeks 60 and 72.
Evaluation of HCV Sequence
Blood samples were obtained for viral sequencing 
at baseline and at every treatment and follow-up 
study visit. Sequencing samples from all the pa-
tients were analyzed at baseline, and those from 
patients who did not meet the criteria for a sus-
tained virologic response were analyzed at all 
post-baseline time points at which HCV RNA levels 
were above the limit of detection of the sequenc-
ing assay (approximately 1000 IU per milliliter). 
HCV RNA was isolated from the plasma and am-
plified by reverse-transcriptase polymerase chain 
reaction, and the NS3/4A region of the HCV ge-
nome was analyzed with the use of population 
sequencing.
Safety Assessments
Chemical and hematologic assessments were per-
formed at the same time as the efficacy assess-
ments during the treatment period and at 4 weeks 
after the last dose of the study drug was admin-
istered. Data on adverse events were collected at 
each treatment visit and at the safety follow-up 
assessment. Full physical examinations were per-
formed at the screening visit and at the safety 
follow-up assessment. Physical examinations were 
performed as needed for the assessment and treat-
ment of symptoms during treatment visits.
Because an increased rate of rash had been 
observed in phase 2 studies,8-10 guidance regarding 
the grading and management of rash was incorpo-
rated into this study. Rash was classified as grade 
1 (mild, localized), grade 2 (moderate, with a dif-
fuse skin eruption involving up to 50% of the body 
surface), or grade 3 (severe, involving more than 
50% of the body surface, or rash with the appear-
ance of substantial systemic signs or symptoms). 
If a progressive grade 2 rash or any grade 3 rash 
developed, telaprevir or placebo was to be discon-
tinued but the patient would continue to receive 
peginterferon–ribavirin. If the rash worsened with-
in 7 days after discontinuation of telaprevir or pla-
cebo, ribavirin (with or without peginterferon) was 
to be discontinued (sequential discontinuation).
Anemia was to be managed by means of re-
ductions in the dose of ribavirin in accordance 
with the product labeling. Erythropoietin-stimu-
lating agents were prohibited according to the 
final amended study protocol, as were reductions 
in the dose of telaprevir. If ribavirin was discon-
tinued owing to anemia, discontinuation of tela-
previr (or placebo) was required.
An independent data and safety monitoring 
committee conducted regular planned reviews of 
the safety data to evaluate safety and side effects 
of the study regimens. The analyses and prepa-
ration of the safety data for each review of the 
committee were performed by a statistical group 
that was independent of the sponsor (Parexel In-
ternational). No interim analyses were planned or 
conducted.
End Points
The primary end point was the proportion of pa-
tients who had undetectable plasma HCV RNA 
24 weeks after the last planned dose of study 
treatment (sustained virologic response). Second-
ary efficacy end points included the proportion of 
patients with undetectable HCV RNA at week 72; 
at week 4, week 12, or both weeks 4 and 12; at the 
end of treatment; and 12 weeks after the last 
planned dose of treatment. A patient was consid-
ered to have had a relapse if he or she had unde-
tectable HCV RNA levels at the end of the treat-
ment period but had confirmed detectable HCV 
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RNA levels sometime between the end of treatment 
and 24 weeks after the last study dose.
Statistical Analysis
The analysis of the primary end point was based 
on a logistic-regression model, with sustained viro-
logic response as the dependent variable and treat-
ment, genotype 1 subtype, and baseline HCV RNA 
plasma level as factors. The primary end point was 
also evaluated by an analysis of the consistency 
of the treatment effect in prespecified subgroups 
according to 10 baseline variables (see the statis-
tical analysis plan provided with the protocol at 
NEJM.org). We estimated that with a sample size 
of 350 patients in each treatment group, the study 
would have 92% power to show a significant dif-
ference among the treatments, with the use of a 
two-sided, continuity-corrected chi-square test, at 
an overall significance level of 5% (adjusted for 
multiple comparisons), assuming a 50% response 
rate in the control (PR) group and a 64% response 
rate in a telaprevir group. Efficacy and safety anal-
yses included data from all patients who underwent 
random assignment and received at least one dose 
of any study drug.
R esult s
Study Patients
Of the 1095 patients enrolled in the study, 1088 
received at least one dose of a study drug and 
were included in the data set for the full analysis 
(Fig. 1). Patients were well balanced with respect 
to major baseline demographic and disease char-
acteristics (Table 1). A total of 58% of the patients 
were men, 9% were black, 11% were Hispanic, 
and 21% had bridging fibrosis or cirrhosis.
Efficacy
A significantly greater proportion of patients in 
each of the two groups receiving telaprevir than in 
the group receiving peginterferon–ribavirin alone 
met the criteria for a sustained virologic response 
(undetectable plasma HCV RNA 24 weeks after 
the last planned dose of study treatment): 75% in 
the T12PR group and 69% in the T8PR group, as 
compared with 44% in the PR group (P<0.001 for 
the comparison of either telaprevir group with the 
PR group) (Table 2). A total of 73% of patients in 
the T12PR group, 67% in the T8PR group, and 44% 
in the PR group had undetectable HCV RNA 72 
weeks after starting treatment (P<0.001 for the 
comparison of either telaprevir group with the PR 
group); 68%, 66%, and 9% in the three groups, 
respectively, had undetectable HCV RNA at week 
4 (rapid virologic response); and 58%, 57%, and 8% 
in the three groups, respectively, had undetectable 
HCV RNA at weeks 4 and 12 (extended rapid viro-
logic response). Among the patients with extended 
rapid virologic response assigned to receive a total 
of 24 weeks of therapy, 89% in the T12PR group 
and 83% in the T8PR group met the criteria for 
sustained virologic response. Mean HCV RNA lev-
els during treatment are shown in Figure 2 in the 
Supplementary Appendix, available at NEJM.org.
Analyses of subgroups according to various 
characteristics showed that there were higher rates 
of sustained virologic response with telaprevir than 
with peginterferon–ribavirin alone (Fig. 2, and 
Fig. 1 in the Supplementary Appendix). A sustained 
virologic response occurred in 71% of the patients 
with HCV genotype 1a and 79% with genotype 
1b in the T12PR group, in 66% and 74% of the 
patients with genotype 1a and genotype 1b, re-
spectively, in the T8PR group, and in 41% and 48% 
in of the patients with genotype 1a and genotype 
1b, respectively, in the PR group. Among black 
patients, 62% in the T12PR group and 58% in the 
T8PR group had a sustained virologic response, 
as compared with 25% in the PR group. Among 
patients with HCV RNA levels of 800,000 IU per 
milliliter or more at baseline, those who received 
telaprevir had a higher rate of response than did 
those who received peginterferon–ribavirin alone 
(74% of the patients in the T12PR group and 66% 
in the T8PR group vs. 36% in the PR group). 
Among patients with bridging fibrosis or cirrho-
sis, 62% of patients in the T12PR group and 53% 
in the T8PR group, as compared with 33% in the 
PR group, had a sustained virologic response.
Among patients who had undetectable HCV 
RNA levels after the last dose of study treatment, 
relapse occurred in 9% in the T12PR group, 9% in 
the T8PR group, and 28% in the PR group. Recipi-
ents of a telaprevir-based regimen who were as-
signed to 24 weeks of treatment and who met 
the criteria for sustained virologic response were 
assessed for relapse beyond 24 weeks after the last 
study dose. One of 357 patients evaluated through 
week 72 (<1%) had a confirmed late relapse after 
early discontinuation of the T8PR regimen at 
week 12. Three others had detectable HCV RNA 
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below 25 IU per milliliter; in 2 of these patients, 
HCV RNA was subsequently undetectable, and 
in 1, there was no available confirmation of HCV 
RNA level. One patient had HCV RNA of more 
than 20 million IU per milliliter, but the se-
quencing assay (limit of detection, approximately 
1000 IU per milliliter) was unsuccessful, raising 
the possibility of a sample error.
A patient was considered to have virologic fail-
ure during the treatment period if he or she met 
the criteria for a stopping rule, had HCV RNA 
greater than 1000 IU per milliliter at week 12 even 
if the HCV RNA decline was greater than 2 log10, 
or had detectable HCV RNA at the end of treat-
ment (week 24 or 48). The rate of virologic failure 
during the treatment period was lower among pa-
tients who received telaprevir than among those 
who received peginterferon–ribavirin alone (8% in 
365 Were assigned to the T12PR
group
363 Received at least one dose
of study drugs
2 Did not receive study drugs
271/363 (75%) Had SVR
210 Were assigned to
24 wk of treatment
195 Completed
treatment
15 Discontinued
treatment
9 Had adverse
event
1 Had virologic
failure
5 Had other
reason
153 Were assigned to
48 wk of treatment
73 Completed
treatment
80 Discontinued
treatment
27 Had adverse
event
4 Were lost to
follow-up
37 Had virologic
failure
12 Had other
reason
202 Completed treatment
159 Discontinued treatment
26 Had adverse event
1 Died
4 Were lost to follow-up
2 Withdrew consent
118 Had virologic failure
8 Had other reasons
158/361 (44%) Had SVR
1095 Patients underwent randomization
207 Were assigned to
24 wk of treatment
191 Completed
treatment
16 Discontinued
treatment
10 Had adverse
event
1 Was lost to
follow-up
5 Had other
reason
157 Were assigned to
48 wk of treatment
69 Completed
treatment
88 Discontinued
treatment
27 Had adverse
event
2 Were lost to
follow-up
1 Withdrew
consent
40 Had virologic
failure
18 Had other
reason
250/364 (69%) Had SVR
365 Were assigned to the T8PR group
364 Received at least one dose
of study drugs
1 Did not receive study drugs
365 Were assigned to the PR (control)
group
361 Received at least one dose
of study drugs
4 Did not receive study drugs
Figure 1. Randomization and Sustained Virologic Response (SVR) in Study Patients.
The T12PR group was assigned to receive telaprevir combined with peginterferon alfa­2a and ribavirin for 12 weeks, followed by peg­
interferon–ribavirin alone for 12 weeks if hepatitis C virus (HCV) RNA was undetectable at weeks 4 and 12 or for 36 weeks if HCV RNA 
was detectable at either time point; the T8PR group was assigned to receive telaprevir with peginterferon–ribavirin for 8 weeks and tela­
previr­matched placebo plus peginterferon–ribavirin for 4 weeks, followed by peginterferon–ribavirin alone for 12 weeks if HCV RNA 
was undetectable at weeks 4 and 12 or by peginterferon–ribavirin for 36 weeks if HCV RNA was detectable at either time point; the PR 
(control) group was assigned to receive telaprevir­matched placebo plus peginterferon–ribavirin for 12 weeks, followed by peginterfer­
on–ribavirin alone for 36 weeks. Of the 1095 patients who underwent randomization, 1088 received at least one dose of the study drugs 
and 7 did not receive any study drugs. In the T12PR group, 3 patients had an extended rapid virologic response but were assigned to the 
48­week treatment group, and 1 patient who did not have an extended rapid virologic response was assigned to receive 24 weeks of 
treatment; however, this patient also met the week­12 stopping rule and discontinued treatment after the week­12 visit.
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the T12PR group and 13% in the T8PR group, vs. 
32% in the PR group). There were similar rates of 
virologic failure in the T12PR group and the T8PR 
group during the telaprevir treatment phase up to 
week 12 (3%), and the virologic failure was attrib-
utable primarily to higher-level resistant variants 
of the HCV virus (e.g., V36M+R155K). After week 
12, the rates of virologic failure were higher in the 
T8PR group than in the T12PR group (10% vs. 5%), 
with more frequent emergence of wild-type and 
lower-level resistant variants (e.g., V36A/M, T54A, 
and R155K/T).11 Virologic failure was more com-
mon among patients with HCV genotype 1a infec-
tion than among those with HCV genotype 1b in-
fection.
Safety
The incidence of gastrointestinal disorders (nausea 
and diarrhea), pruritus, rash, and anemia was at 
least 10 percentage points higher in either of the 
telaprevir groups than in the PR group (Table 3). 
Other common adverse events are shown in Table 1 
in the Supplementary Appendix. A total of 10% of 
the patients in the T12PR group, 10% in the T8PR 
group, and 7% in the PR group discontinued all 
treatment at some time during the study owing to 
adverse events (Table 2 in the Supplementary Ap-
pendix), whereas 7%, 8%, and 4% of the patients 
in the three groups, respectively, discontinued all 
treatment during the telaprevir (or placebo) phase 
of the study owing to adverse events. The rate of 
Table 1. Baseline Characteristics of the Study Patients, According to Treatment Group.*
Characteristic
T12PR 
(N = 363)
T8PR 
(N = 364)
PR 
(N = 361)
Age — yr
Median 49 49 49
Range 19–69 19–68 18–69
Body­mass index†
Median 25.7 26.2 26.4
Range 18–47 17–46 17–48
Distribution — no. (%)
<25 155 (43) 145 (40) 130 (36)
25 to <30 129 (36) 131 (36) 144 (40)
≥30 77 (21) 86 (24) 87 (24)
Male sex — no. (%) 214 (59) 211 (58) 211 (58)
Race — no. (%)‡
White 325 (90) 315 (87) 318 (88)
Black 26 (7) 40 (11) 28 (8)
Asian 5 (1) 5 (1) 10 (3)
Other 7 (2) 4 (1) 5 (1)
Ethnic group — no. (%)‡
Hispanic 35 (10) 44 (12) 38 (11)
Non­Hispanic 328 (90) 320 (88) 323 (89)
Alanine aminotransferase — IU/liter 84±69 80±62 88±67
Total bilirubin — µmol/liter§ 10±5 9±4 9±4
Serum albumin — g/liter 45±3 44±3 44±3
Platelet count — ×10−9/liter 250±73 236±65 243±70
HCV subtype — no. (%)¶
1a 213 (59) 210 (58) 208 (58)
1b 149 (41) 151 (41) 151 (42)
Unknown 1 (<1) 3 (1) 2 (1)
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discontinuation of telaprevir (or placebo) only ow-
ing to adverse events was higher among the pa-
tients who received telaprevir than among those 
who received placebo (11% in the T12PR group and 
7% in the T8PR group, vs. 1% in the PR group). 
Anemia and rash were the most frequently re-
ported adverse events that led to the discontinua-
tion of telaprevir-based regimens. A total of 7% 
of the patients in the T12PR group and 5% in the 
T8PR group discontinued telaprevir owing to rash, 
whereas 1.4% and 0.5% in the two groups, respec-
tively, discontinued all treatment owing to rash 
during the telaprevir (or placebo) phase of the study. 
Rashes were primarily eczematous and were re-
versible with discontinuation of telaprevir. One case 
of the Stevens–Johnson syndrome occurred approx-
imately 11 weeks after the last dose of telaprevir 
had been administered.
More patients in the telaprevir groups than 
in the PR group discontinued all treatment ow-
ing to anemia (1% in the T12PR group and 3% 
in the T8PR group, vs. <1% in the PR group), 
and 4%, 2%, and 0% of the patients in the three 
groups, respectively, discontinued telaprevir (or 
placebo) only. A total of 17 patients in the T12PR 
group, 17 in the T8PR group, and 6 in the PR 
group received blood transfusions during the 
study. The decrease in hemoglobin levels was 
more pronounced in patients receiving telaprevir-
based regimens than in patients in the PR group 
and was reversed with the discontinuation of 
telaprevir (Fig. 3 in the Supplementary Appendix). 
The largest difference in mean hemoglobin levels 
between the T12PR group and the PR group 
(1.04 g per deciliter lower in the T12PR group) and 
between the T8PR group and the PR group (1.11 g 
per deciliter lower in the T8PR group) was ob-
served at week 8 of treatment.
Four deaths occurred during the study: three 
after all study drugs had been discontinued and 
one (in the PR group) during the treatment phase. 
Two patients — one in the T12PR group and one 
in the PR group — died as a result of suicide, one 
patient in the T12PR group died from HCV infec-
tion and liver disease, and one in the T8PR group 
died from an unknown cause.
Discussion
These results confirm earlier studies and showed 
a significant increase in the rate of sustained viro-
logic response among patients with HCV genotype 
1 infection who are treated with a regimen combin-
ing peginterferon alfa-2a and ribavirin with tela-
Table 1. (Continued.)
Characteristic
T12PR 
(N = 363)
T8PR 
(N = 364)
PR 
(N = 361)
HCV RNA — log10 IU/ml‖ 6.3±0.7 6.3±0.7 6.3±0.7
HCV RNA ≥800,000 IU/ml — no. (%)‖ 281 (77) 279 (77) 279 (77)
Stage of fibrosis and cirrhosis — no. (%)
None or minimal fibrosis 134 (37) 128 (35) 147 (41)
Portal fibrosis 156 (43) 151 (41) 141 (39)
Bridging fibrosis 52 (14) 59 (16) 52 (14)
Cirrhosis 21 (6) 26 (7) 21 (6)
* Plus–minus values are means ±SD. The PR (control) group received telaprevir­matched placebo plus peginterferon alfa­
2a and ribavirin for the first 12 weeks followed by peginterferon–ribavirin for 36 weeks. The telaprevir groups received 
telaprevir for 8 weeks (T8PR) or 12 weeks (T12PR), as well as peginterferon–ribavirin for a total of 24 weeks or 48 
weeks. There were no significant differences in the listed characteristics among the telaprevir groups and the control 
group, except for body­mass index, for which there was a significant difference between the T12PR group and the PR 
group (P = 0.02).
† The body­mass index is the weight in kilograms divided by the square of the height in meters.
‡ Race and ethnic group were self­reported and were not mutually exclusive.
§ To convert the values for total bilirubin to milligrams per deciliter, divide by 17.1.
¶ Hepatitis C virus (HCV) genotype and subtype were determined with the use of the VERSANT HCV genotype 2.0 assay 
(INNO­LiPA, Innogenetics).
‖ HCV RNA levels were measured with the use of COBAS TaqMan HCV assay (Roche), which has a lower limit of quanti­
fication of 25 IU per milliliter and a lower limit of detection of 10 IU per milliliter.
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previr for 12 or 8 weeks, followed by peginterferon–
ribavirin alone, for a total of 24 or 48 weeks of 
therapy, as compared with a standard regimen of 
peginterferon–ribavirin alone for 48 weeks. Among 
patients with HCV genotype 1 infection who have 
not previously received treatment, the potential 
to shorten the duration of therapy with peginter-
feron–ribavirin to less than 48 weeks without im-
pairing the chance of a sustained virologic re-
sponse is currently limited to the small number of 
patients with a low viral load who have undetect-
able HCV RNA at week 4.12-15 In contrast, in the 
current study, more than half the patients who 
received telaprevir had undetectable HCV RNA at 
weeks 4 and 12, indicating an extended rapid viro-
logic response, and relapse occurred infrequently 
in these patients after 24 weeks of treatment, sug-
gesting that a total treatment duration of 24 weeks 
is sufficient for these patients. A longer duration 
of peginterferon–ribavirin therapy is indicated for 
patients who do not have an extended rapid viro-
logic response.
Patients in the T8PR group, as compared with 
those in the T12PR group, had a lower rate of 
response, and also a slightly lower rate of dis-
continuation of telaprevir. The lower rate of viro-
logic failure during treatment in the T12PR group 
as compared with the T8PR group and the more 
frequent emergence of wild-type and lower-level 
resistant variants beyond week 12 in the T8PR 
group than in the T12PR group are probably at-
tributable to more efficient elimination of these 
viral strains as a result of the additional 4 weeks 
of telaprevir therapy in the T12PR group.
The rates of sustained virologic response were 
substantially improved with the addition of tela-
previr in patients with negative predictive factors 
for a response to peginterferon–ribavirin treat-
ment, such as bridging fibrosis or cirrhosis, older 
age, diabetes, and HCV RNA levels of 800,000 IU 
per milliliter or more. An increase in sustained 
virologic response by a factor of more than 2 oc-
curred with telaprevir in black patients, in whom 
low response rates to interferon have been re-
Table 2. Response during and after the Treatment Period, According to Treatment Group.
Response
T12PR  
(N = 363)
T8PR  
(N = 364)
PR  
(N = 361)
Undetectable HCV RNA during treatment period — no. (%)*
At week 4 246 (68) 242 (66) 34 (9)
At weeks 4 and 12 212 (58) 207 (57) 29 (8)
Undetectable HCV RNA at end of treatment period — no. (%) 314 (87) 295 (81) 229 (63)
Undetectable HCV RNA 24 wk after end of treatment: sustained 
virologic response — no./total no. (%)†
All patients‡ 271/363 (75) 250 /364(69) 158/361 (44)
Patients with undetectable HCV RNA at weeks 4 and 12 189/212 (89) 171/207 (83) 28/29 (97)
Patients with detectable HCV RNA at weeks 4 or week 12 82/151 (54) 79/157 (50) 130/332 (39)
Patients with undetectable HCV RNA at week 4 206/246 (84) 188/242 (78) 32/34 (94)
Patients with detectable HCV RNA at week 4 65/117 (56) 62/122 (51) 126/327 (39)
Undetectable HCV RNA at 72 wk — no. (%)§ 265 (73) 243 (67) 158 (44)
Relapse among patients with undetectable HCV RNA at end of 
treatment period — no./total no. (%)
All patients 27/314 (9) 28/295 (9) 64/229 (28)
Patients who completed treatment 17/264 (6) 18/247 (7) 51/189 (27)
* Patients with undetectable HCV RNA at week 4 met the criterion for a rapid virologic response, and patients with unde­
tectable HCV RNA at weeks 4 and 12 met the criterion for an extended rapid virologic response.
† Sustained virologic response (undetectable HCV RNA 24 weeks after the end of treatment) was the primary end point.
‡ All patients who received at least one dose of study drug were included in the analysis. The difference in response rates 
was 31 percentage points (95% confidence interval [CI], 24 to 38) between the T12PR and PR groups and 25 percentage 
points (95% CI, 18 to 32) between the T8PR and PR groups.
§ The 72­week assessment was performed 24 weeks after the end of treatment in patients who received 48 weeks of treat­
ment and 48 weeks after end of treatment in patients who received 24 weeks of treatment.
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ported.16-19 This finding has been associated with 
a high prevalence in black persons of the T allele 
at the rs1297860 locus in the region of the IL28B 
gene.20,21 Additional studies are needed to clarify 
the relationship between IL28B polymorphisms 
and the response to telaprevir or other direct-
acting antiviral agents.
As suggested previously, telaprevir, as compared 
with peginterferon–ribavirin alone, was associat-
ed with a higher incidence of adverse events such 
−0.2 0.0 0.80.60.40.2
T12PR BetterPR  Better
Sex
Male
Female
Age
≤45 yr
>45 to ≤65 yr
Race
White
Black
Ethnic group
Hispanic
Non-Hispanic
HCV subtype
1a
1b
Baseline HCV RNA levels (IU/ml)
<800,000
≥800,000
Fibrosis status
No or minimal fibrosis
Portal fibrosis
Bridging fibrosis
Cirrhosis
Body-mass index
<25 (normal)
≥25 to <30 (overweight)
≥30 (obese)
History of diabetes
Yes
No
Geographic region
North America
Europe
Other
T12PR Difference in Rate of SVR (95% CI)PRSubgroup
−0.4
  94/211 (45)
  64/150 (43)
  74/143 (52)
  82/216 (38)
147/318 (46)
  7/28 (25)
15/38 (39)
143/323 (44)
  85/208 (41)
  73/151 (48)
57/82 (70)
101/279 (36)
  67/147 (46)
  67/141 (48)
17/52 (33)
  7/21 (33)
  57/130 (44)
  65/144 (45)
36/87 (41)
  6/21 (29)
152/340 (45)
  89/214 (42)
  49/106 (46)
20/41 (49)
159/214 (74)
112/149 (75)
118/142 (83)
150/214 (70)
244/325 (75)
16/26 (62)
26/35 (74)
245/328 (75)
152/213 (71)
118/149 (79)
64/82 (78)
207/281 (74)
109/134 (81)
117/156 (75)
32/52 (62)
13/21 (62)
129/155 (83)
  87/129 (67)
55/77 (71)
15/21 (71)
256/342 (75)
156/214 (73)
  80/104 (77)
35/45 (78)
no. of patients/total no. (%)
Figure 2. Difference in Rates of Sustained Virologic Response (SVR) between the T12PR and Control Groups,
According to Subgroups.
The T12PR group was assigned to receive telaprevir combined with peginterferon alfa­2a and ribavirin for 12 weeks, 
followed by peginterferon–ribavirin alone for 12 weeks if hepatitis C virus (HCV) RNA was undetectable at weeks  
4 and 12 or for 36 weeks if HCV RNA was detectable at either time point; the PR (control) group was assigned to  
receive telaprevir­matched placebo plus peginterferon–ribavirin for 12 weeks, followed by peginterferon–ribavirin 
alone for 36 weeks. The position of each square indicates the point estimate of the benefit associated with telaprevir 
for each subgroup; the horizontal lines indicate 95% confidence intervals. Race and ethnic group were self­reported. 
The body­mass index is the weight in kilograms divided by the square of the height in meters. Geographic regions 
other than North America and Europe included Argentina, Australia, and Israel. Results are presented for subgroups 
with at least 10 patients per treatment group. For similar analyses comparing the T8PR group with the PR group, see 
the Supplementary Appendix.
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Table 3. Incidence of Serious Adverse Events and Most Common Adverse Events, According to Treatment Group.*
Adverse Event
T12PR  
(N = 363)
T8PR
(N = 364)
PR
(N = 361)
number (percent)
Serious adverse event 33 (9) 31 (9) 24 (7)
Infection
Cellulitis 1 (<1) 1 (<1) 1 (<1)
Pneumonia 1 (<1) 2 (1) 0
Anemia 8 (2) 10 (3) 4 (1)
Rash 2 (1) 3 (1) 0
Syncope 3 (1) 0 0
Psychiatric disorders 2 (1) 1 (<1) 3 (1)
Musculoskeletal disorders 2 (1) 0 3 (1)
Cardiac disorders 2 (1) 0 2 (1)
Renal and urinary disorders 0 0 4 (1)
Eye disorders 1 (<1) 1 (<1) 1 (<1)
Hepatobiliary disorders 2 (1) 1 (<1) 0
Vascular disorders 1 (<1) 1 (<1) 1 (<1)
Any adverse event 361 (99) 362 (99) 354 (98)
General disorders
Fatigue 207 (57) 211 (58) 206 (57)
Pyrexia 95 (26) 108 (30) 87 (24)
Gastrointestinal disorders
Nausea 156 (43) 146 (40) 112 (31)
Diarrhea 102 (28) 115 (32) 80 (22)
Skin and subcutaneous­tissue disorders
Pruritus 181 (50) 165 (45) 131 (36)
Rash† 133 (37) 129 (35) 88 (24)
Headache 148 (41) 156 (43) 142 (39)
Anemia‡ 135 (37) 141 (39) 70 (19)
Insomnia 117 (32) 116 (32) 111 (31)
Musculoskeletal disorders 142 (39) 148 (41) 179 (50)
Infections and infestations 103 (28) 135 (37) 136 (38)
Metabolic and nutrition disorders 111 (31) 109 (30) 86 (24)
* The serious adverse events listed here are those that were reported in at least three patients during the treatment period, 
and the other adverse events listed are those that were reported during the treatment period in at least 30% of patients 
in at least one of the three study groups; all grades of events are included. Other common adverse events, including 
anorectal symptoms, are shown in Table 1 in the Supplementary Appendix. Adverse events in bold are those that occurred 
at an incidence that was 10 percentage points higher in either group receiving telaprevir than in the PR (control) group.
† As assessed with the use of a group of related terms to identify all dermatologic events, the incidences of rash events 
and grade 3 rash events were 61% and 6%, respectively, in the T12PR group, 58% and 4%, respectively, in the T8PR 
group, and 48% and 1%, respectively, in the PR group during the overall treatment phase.
‡ The percentages of patients with hemoglobin levels of less than 10 g per deciliter and less than 8.5 g per deciliter were 
36% and 9%, respectively, in the T12PR group, 40% and 9%, respectively, in the T8PR group, and 14% and 2%, respec­
tively, in the PR group.
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as rash, gastrointestinal disorders, and anemia.8-10 
In this study, rashes resolved with the discontinu-
ation of telaprevir; 7 to 11% of patients discontin-
ued telaprevir, and only 0.5 to 1.4% discontinued 
all therapy owing to rash. The implementation of 
managed, sequential discontinuation of medica-
tions for severe rash may have led to the lower rate 
of overall discontinuation of treatment in this 
study. Anemia led to the discontinuation of treat-
ment in few patients.
In conclusion, telaprevir-containing regimens, 
as compared with a regimen of peginterferon–
ribavirin alone, were associated with a significant 
increase in the rates of sustained virologic re-
sponse, overall and in all the subgroups of patients 
that were analyzed. The majority of patients who 
were treated with telaprevir had undetectable HCV 
RNA at weeks 4 and 12 and received only 24 weeks 
of total therapy. Numerically higher response rates, 
with a small increment in reversible adverse events, 
were observed with a regimen of 12 weeks, as 
compared with 8 weeks, of telaprevir combined 
with peginterferon–ribavirin, followed by addi-
tional weeks of peginterferon–ribavirin alone. The 
significant improvement in the rates of sustained 
virologic response with telaprevir-based therapy 
and the capacity for response-guided therapy to 
shorten the duration of exposure to peginterferon–
ribavirin among patients who have a rapid re-
sponse represent important advances in the treat-
ment of patients with HCV genotype 1 infection.
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